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Mutations in ﬁlamin C cause a new form of familial
hypertrophic cardiomyopathy
Rafael Valde´s-Mas1,*, Ana Gutie´rrez-Ferna´ndez1,*, Juan Go´mez2, Eliecer Coto2,3, Aurora Astudillo4,
Diana A. Puente1, Julia´n R. Reguero5, Victoria A´lvarez2, Ce´sar Morı´s3,5, Diego Leo´n5, Marı´a Martı´n5,
Xose S. Puente1 & Carlos Lo´pez-Otı´n1
Mutations in different genes encoding sarcomeric proteins are responsible for 50–60% of
familial cases of hypertrophic cardiomyopathy (HCM); however, the genetic alterations
causing the disease in one-third of patients are currently unknown. Here we describe a case
with familial HCM of unknown cause. Whole-exome sequencing reveals a variant in the gene
encoding the sarcomeric protein ﬁlamin C (p.A1539T) that segregates with the disease in
this family. Sequencing of 92 HCM cases identiﬁes seven additional variants segregating with
the disease in eight families. Patients with FLNC mutations show marked sarcomeric
abnormalities in cardiac muscle, and functional analysis reveals that expression of these FLNC
variants resulted in the formation of large ﬁlamin C aggregates. Clinical studies indicate that
FLNC-mutated patients have higher incidence of sudden cardiac death. On the basis of these
ﬁndings, we conclude that mutations in the gene encoding the sarcomeric protein ﬁlamin
C cause a new form of familial HMC.
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H
ypertrophic cardiomyopathy (HCM) is a relatively
frequent and potentially devastating disease, which affects
1:500 individuals and represents one of the main causes of
sudden cardiac death among young adults1,2. The study of
familial HCM cases has revealed that mutations in at least 11
different genes encoding sarcomeric proteins are responsible for
50–60% of these familial cases3,4. However, in about one-third of
patients with a family history of HCM, the genetic alterations
causing the disease are currently unknown, and this rate is higher
among apparently sporadic cases. This fact prevents the
identiﬁcation of individuals at the risk of heart failure that can
lead to heart transplantation or sudden death.
The identiﬁcation of genes responsible for HCM has mainly
relied on linkage analysis in large pedigrees3. However, this
approach is not suitable for the study of more common smaller
pedigrees due to the lack of statistical power. The recent
development of next-generation sequencing methods represents
a powerful and unbiased strategy to uncover the genetic changes
that are responsible for hereditary diseases5–7.
Here we perform exome-capture followed by next-generation
sequencing to identify the putative genetic alterations present in
one family with HCM that lacked mutations in known genes
involved in this disease. On the basis of these studies, together
with additional genome sequencing analysis of 92 subjects with
HCM, we suggest that mutations in the FLNC gene encoding the
sarcomeric protein ﬁlamin C are a novel cause of HCM.
Results
Study subjects. A 53-year-old woman (patient CAR2_III-1) was
diagnosed with HCM at 20 years of age on the basis of published
criteria, including electrocardiography showing left ventricular
hypertrophy and echocardiography showing a hypertrophic sep-
tum (27mm)8,9. She was treated with beta-blockers, but 12 years
later developed atrial ﬁbrillation and received an electrical
cardioversion and was treated with amiodarone. After a second
failed cardioversion, magnetic resonance with late gadolinium
enhancement showed extensive areas of ﬁbrosis affecting the
septum, apex and anterior wall. She received an implantable
cardioverter deﬁbrillator (ICD), without discharges to date.
Currently, she is under treatment with beta-blockers, in NYHA
grade I and with a left-ventricular outﬂow obstruction (LVOTO) of
30mmHg. The case is consistent with familial HCM based on the
presence of additional members of the family with HCM. The
pedigree of this family and the main characteristics of the affected
members are shown in Fig. 1 and Supplementary Table 1,
respectively. Thus, her mother suffered sudden death during labor
at 34 years of age, and her grandmother and grand-aunt died at the
age of 62 and 55, respectively, from cardiac causes. Two additional
relatives (CAR2_II-7 and CAR2_II-9) (Fig. 1) were diagnosed with
HCM at 45 and 82 years of age. Nucleotide-sequencing analysis of
all coding exons plus intronic ﬂanking regions of sarcomeric genes
previously associated with HCM, including MYH7, MYBPC3,
TNNT2, TNNI3, TPM1, ACTC1, TNNC1, MYL2 and MYL3, failed
to show any mutation in this patient.
Exome sequencing of a patient with familial HCM. Exome
sequencing was performed on patient CAR2_III-1 (Fig. 1). More
than 80% of the exome regions were callable and 19,467 variants
were identiﬁed. We conﬁrmed that no mutations in genes pre-
viously associated with HCM were present in this patient. After
removing common polymorphisms, a total of 128 variants
potentially affecting protein function due to the introduction of
missense, nonsense, splicing or frameshifts in the coding regions
were identiﬁed in this patient (Supplementary Table 1). From
these gene variants, we searched for those predicted to affect the
function of the protein and presenting cardiac-speciﬁc expression,
with the ﬁnding that FLNC—encoding the muscle-speciﬁc ﬁlamin
C and implicated in myocyte differentiation—had a missense
mutation in this patient (p.A1539T). This ﬁlamin is localized at
the Z-discs of the sarcomere and interacts with other sarcomeric
proteins, including myozenin-2 and myotilin10,11. To further
evaluate the possibility that FLNC could be a novel gene
associated with familial HCM, we next analysed whether the
FLNC variant identiﬁed in this patient segregated with the disease
in this family. Analysis of nine available members of this pedigree
(four affected and ﬁve non-affected) (Fig. 1) revealed that the
identiﬁed variant (p.A1539T) segregated with the disease. Three
additional members of the family (I-1, II-1 and I-6), who were
obligate carriers of the FLNC p.A1539T variant but for which
DNA was not available for analysis, died due to cardiac failure
and were considered affected for the purpose of this analysis.
Individual II-4, deceased at the age of 90, did not show symptoms
of HCM, had normal electrocardiograms and was considered
non-affected, although lack of DNA from this individual
prevented genotyping. Inclusion of those obligate carriers in the
analysis resulted in evidence of linkage between the FLNC variant
p.A1539T and HCM in this family (LOD score¼ 2.33).
FLNC variants in families with HCM. To examine whether
FLNC variants could be also present in other families with HCM,
we performed nucleotide-sequencing analysis of the 48 FLNC
coding exons in an additional set of 92 HCM cases (19% with
familial HCM and 81% apparently sporadic) who were negative for
mutations in the aforementioned sarcomeric genes, using pooled-
PCRs followed by next-generation sequencing. This study revealed
six additional unique missense variants and a nonsense variant
(Fig. 1 and Table 1). Overall, we identiﬁed eight unique variants in
a total of nine subjects with HCM. Sequencing of available family
members resulted in the ﬁnding of 18 additional subjects carrying
the identiﬁed FLNC variants in the index cases (Supplementary
Table 2). None of these FLNC variants were present in 4400
subjects of the Spanish population, 1000genomes or the exome-
sequencing project (ESP), with the exception of variant p.A2430V,
for which 2 alleles, out of 12,624 analysed, were identiﬁed in the
ESP. Variant FLNC p.A2430V is the only one classiﬁed as neutral
by the SIFT prediction server, and therefore this variant might
constitute a rare polymorphism in the FLNC gene, although the
presence of individuals with HCM on the ESP project cannot be
ruled out. To determine whether the number of patients with
FLNC mutations observed in our sample was different from that
expected in the general population, we compared these results with
those of the ESP project for the European–American population.
We found 98 out of 4,200 individuals from the ESP project with
variants predicted as deleterious by SIFT and PolyPhen, including
some frameshifts and stop codons in the C-terminal region similar
to those described for myoﬁbrillar myopathy12. By contrast, we
had seven patients out of 92 with FLNC variants predicted as
deleterious by both algorithms (Fisher’s Exact Test P¼ 0.0068,
OR¼ 3.44, 95% CI: 1.31–7.68), indicating that is unlikely to obtain
this distribution of mutations by chance. In addition, we observed
strong cosegregation of FLNC variants and clinical status among
eight families affected by HCM (Fig. 2 and Supplementary Table 2)
(combined LINKAGE LOD score¼ 4.1). Among the 16
individuals carrying a FLNC variant who were older than 40,
and for whom data were available, 14 had HCM symptoms,
resulting in a penetrance 487%. No differences in incidence
between males and females, age at diagnosis, left ventricular
obstruction tract outﬂow or the presence of cardiac symptoms
were observed between subjects with or without variants in FLNC
(Supplementary Table 3). Septums appeared to be thinner in FLNC
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mutation carriers with hypertrophy (n¼ 20; 16 versus 19.2mm,
Po0.05), and the presence of FLNCmutations was associated with
a higher frequency of familial history of HCM (55 versus 17.8%,
Po0.01). Two patients underwent heart transplantation due to
cardiac insufﬁciency secondary to diastolic failure, and both carried
mutations in FLNC (cases CAR242_I-1 and CAR304_II-4).
Interestingly, ﬁve of the nine families with mutations in FLNC
had cases of sudden cardiac death (4 early, 1 late), in comparison
with 23 (10 early, 13 late) out of 84 cases without variants in FLNC
(56 versus 27%, Po0.05).
FLNC variants affect cardiac muscle structure. Interestingly,
mutations in FLNC have been previously associated with myoﬁ-
brillar myopathy (MIM 609524)12,13. However, none of the
patients diagnosed with HCM in our study showed symptoms of
myoﬁbrillar myopathy, including nine subjects older than 44
years, which is the mean age at onset reported for the most
common mutation in FLNC (p.W2710X)13. Four HCM patients
with mutations in FLNC were studied by electromyography and
magnetic resonance imaging with negative results. Histological
analysis of skeletal muscle biopsies from two patients with HCM
and FLNC variants (p.A1539T, case CAR2_III-1, and p.H2315N,
case CAR125_II-2) showed intact sarcomeric structures, normal
ATPase, SDH and NADH staining, as well as the absence of small
aggregates, which are characteristic of myoﬁbrillar myopathy
(Supplementary Fig. 1). The FLNC mRNA expression level in a
skeletal muscle biopsy was similar to that found in individuals
without FLNC mutations (Supplementary Fig. 2). In addition, no
evidence of ﬁlamin C or desmin aggregates, spheroid bodies or
deposits, features typically found in skeletal muscles from subjects
with myoﬁbrillar myopathy and FLNC mutations12,14,15 were
observed in our HCM patients (Supplementary Figs 1 and 2).
Histological analysis of cardiac muscle sections from two
transplanted subjects with FLNC mutations (p.G2151S, case
CAR242_I-1 and p.A1539T, case CAR304_II-4) revealed marked
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Figure 1 | Familial hypertrophic cardiomyopathy due to mutations in FLNC. (a) Pedigree of the affected family (CAR2). Solid symbols indicate affected
subjects, and open symbols unaffected relatives. Squares denote male family members, circles female members and slashed deceased members. Arrow
indicates index case. (b) Partial sequence electropherogram of the FLNC gene with the nucleotide substitution identiﬁed in the three affected members
analysed (family members III-1, II-7 and II-9). The heterozygous mutation c.4824G4A (arrow) causes a missense substitution p.A1539T. (c) Schematic
representation of the ﬁlamin C protein with the position of the eight mutations identiﬁed in this work in patients with HCM (up) as well as the mutations
reported in patients with myoﬁbrillar myopathy (down).
Table 1 | FLNC mutations identiﬁed in families with hereditary cardiomyopathy.
Family DNA variant (hg19) Amino-acid change SIFT prediction PolyPhen prediction Creatine kinase levels
CAR176 chr7:128,471,013 G4T p.E108X Deleterious Probably damaging Normal
CAR84 chr7:128,475,395 T4C p.V123A Deleterious Probably damaging High
CAR195 chr7:128,477,710 C4A p.N290K Deleterious Probably damaging Normal
CAR2 chr7:128,488,649 G4A p.A1539T Deleterious Probably damaging Normal
CAR304 chr7:128,488,649 G4A p.A1539T Deleterious Probably damaging Normal
CAR104 chr7:128,493,805 G4A p.R2133H Deleterious Probably damaging Normal
CAR242 chr7:128,493,858 G4A p.G2151S Deleterious Probably damaging Normal
CAR125 chr7:128,494,682 C4A p.H2315N Deleterious Benign High
CAR240 chr7:128,496,609 C4T p.A2430V Neutral Possibly damaging High
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms6326 ARTICLE
NATURE COMMUNICATIONS | 5:5326 | DOI: 10.1038/ncomms6326 |www.nature.com/naturecommunications 3
& 2014 Macmillan Publishers Limited. All rights reserved.
sarcomeric abnormalities, including myoﬁbrillar disarray, sarco-
meric aggregates and ﬁbrosis not observed in control hearts from
either three HCM patients without mutations in FLNC or from a
healthy subject (Fig. 3 and Supplementary Fig. 3). Electron
microscopy examination showed strong Z-band irregularities and
myoﬁbrillar disarray, as well as rod formation in cardiomyocytes
from these patients. Immunohistochemical staining conﬁrmed
the presence of ﬁlamin C in the sarcomeric aggregates observed in
cardiac myocytes from patients with FLNC mutations (Fig. 3 and
Supplementary Fig. 3). Finally, and similar to subjects with
myoﬁbrillar myopathy, we found that 34% (9/26) of the subjects
with HCM and mutations in FLNC had elevated levels of serum
creatine kinase, in contrast to 6% (5/82) of patients with HCM
and lacking FLNC variants (Po10 4) (Supplementary Table 2).
Serum creatine kinase levels varied from normal to up to sixfold
of the upper normal limit. All nine subjects with elevated serum
creatine kinase levels belonged to three of the seven analysed
families, and in these families all carriers of FLNC variants
(p.V123A, p.H2315N and p.A2430V) showed high creatine
kinase levels.
Functional analysis of FLNC mutations. Notably, all the iden-
tiﬁed FLNC variants affected highly conserved residues in the
protein encoded by this gene, from ﬁsh to human
(Supplementary Fig. 4). We also observed that FLNC variants
were non-randomly distributed within ﬁlamin C (Fig. 1), as they
were mainly clustered on the N-terminal (actin-binding domain
and ﬁrst rod repeat) or C-terminal (last four rod repeats) portions
of the protein. These data strongly suggest that FLNC variants
found in subjects with HCM might impair the function of this
sarcomeric protein. To evaluate this possibility, we generated four
ﬁlamin C full-length cDNA clones containing the p.V123A,
p.A1539T, p.R2133H or p.A2430V mutations identiﬁed in HCM
patients. H9C2 rat cardiac myoblasts were nucleofected with
wild-type FLNC or the mutant constructs, and the formation of
insoluble ﬁlamin C aggregates was determined using sequential
detergent extraction. Western blot analysis revealed that wild-
type FLNC was exclusively present in the soluble fraction, while
three of the four analysed mutants (p.V123A, p.R2133H and
p.A2430V) could be detected in the insoluble fraction (Fig. 4a),
consistent with the formation of protein aggregates when
expressed in cardiac myoblasts. In addition, expression of two of
the analysed mutants (p.A1539T and p.R2133H) also resulted in
the formation of actin aggregates (Fig. 4a).
Similarly, when these mutants were expressed in rat neonatal
cardiac myocytes, we found that they form large ﬁlamin C
aggregates as assessed by immunoﬂuorescence and confocal
microscopy (Fig. 4b). However, wild-type ﬁlamin C expression
resulted in a cytoplasmic distribution, mainly associated with
actin ﬁbres, and absence of aggregate formation (Fig. 4b). We
noticed some variability in the distribution pattern between
different mutants. Interestingly, the p.V123A mutant, which by
confocal microscopy showed the largest aggregates in rat cardiac
myocytes, had also the strongest signal by western blot analysis in
the insoluble fraction, thereby showing a close agreement between
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Figure 2 | Pedigrees of families with mutations in FLNC. Solid symbols indicate affected subjects, and open symbols unaffected relatives. FLNC mutation
carriers are denoted with a ‘þ ’ symbol, and noncarriers with a ‘ ’ symbol.
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microscopic and biochemical methods, and supporting the
formation of aggregates by these ﬁlamin C mutants. Over-
expression of these mutants in C2C12 cell myotubes also resulted
in the formation of protein aggregates, although they were smaller
than those observed in cardiac myocytes (Supplementary
Figs 5 and 6). Together, these data support the hypothesis that
the mutations in ﬁlamin C identiﬁed in HCM patients disrupt the
structure of this sarcomeric protein, leading to the formation of
protein aggregates that might ﬁnally impair sarcomere function.
Discussion
We describe here a family with an autosomal dominant HCM of
unknown genetic basis. By means of whole-exome sequencing of
the index case and subsequent target resequencing of a candidate
gene in an additional set of 92 HCM patients, we have shown
evidence of linkage between mutations in FLNC and familial
HCM in eight independent families of Spanish origin. FLNC
encodes the sarcomeric protein ﬁlamin C, a muscle-speciﬁc
protein involved in myocyte differentiation and muscle function
HE staining
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Electron microscopy
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Figure 3 | Consequences of FLNC mutations in cardiac tissue of HCM patients. (a) H&E staining of heart explants from two transplanted cases shows
sarcomere disarray and aggregates of sarcomeric structures not present in the heart of a healthy control subject. (b) Ultrastructural analysis of cardiac tissue
from the same subjects. Myoﬁbre disarray, sarcomere disorganization and presence of deposits are visible in the cardiac tissue of HCM patients, but not in the
control (magniﬁcation  5,000). (c) Immunohistochemical staining reveals the presence of ﬁlamin C in the protein aggregates (arrows) occurring in
cardiomyocytes of patients with FLNCmutations. Analysis of heart samples from a healthy control as well as three HCM patients, one caused by a mutation in
MYH7, and two without mutations in sarcomeric genes or FLNC, revealed large nuclei and larger ﬁbre diameter, but not ﬁlamin C aggregates.
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by interacting with proteins of both the Z-disc and the
sarcolemma16. Mutations in genes encoding other sarcomeric
proteins, includingMYH7, TPM1, TNNT2,MYL3 and TNNI3, are
responsible for a large fraction of HCM cases, indicating that the
FLNC mutations identiﬁed in this work expand the number of
sarcomeric genes implicated in this pathology.
Mutations in FLNC had been previously shown to be
responsible for myoﬁbrillar myopathy12,13,16. However, none of
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Figure 4 | Functional analysis of FLNC mutants. (a) H9C2 rat cardiac myoblast cells were transiently transfected with expression vectors encoding DDK-
tagged wild-type FLNC or mutants p.V123A, p.A1539T, p.R2133H or p.A2430V. Soluble and insoluble protein extracts were subjected to SDS–PAGE, and
ﬁlamin C or actin was detected by western blot using an anti-DDK or anti-actin antibodies, showing the presence of insoluble ﬁlamin C and actin when
some mutants were expressed. (b) Subcellular distribution of ectopically expressed FLNC wild type and mutants in neonatal rat cardiac myocytes was
analysed by immunoﬂuorescence and confocal microscopy. Filamin C distribution was detected using an anti-DDK antibody, actin ﬁbres were stained with
phalloidin and nuclei were counterstained with DAPI. Ectopic expression of mutant FLNC constructs resulted in the formation of perinuclear protein
aggregates not observed in wild-type FLNC.
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our HCM patients showed symptoms of this ﬁlaminopathy, and
none of the FLNC mutations identiﬁed in our study overlapped
with those reported for myoﬁbrillar myopathy. In fact, analysis of
skeletal muscle biopsies from two HCM patients showed a
normal muscle ﬁbre histology and biochemistry, and lacked any
of the myopathological or electrophysiological abnormalities
described in myoﬁbrillar myopathy patients. These ﬁndings,
together with previous reports showing that different mutations
within the ﬁlamin C molecule result in different myopathological
features16, suggest that ﬁlaminopathies caused by FLNC
mutations are not restricted to skeletal muscle disorders, but
can generate a spectrum of muscle disorders with distinct
involvement of skeletal and cardiac muscle abnormalities. This
intriguing and interesting observation is not unprecedented.
Thus, different mutations in the gene encoding the myosin heavy
chain 7 (MYH7) can result in either Laing-type early-onset distal
myopathy17 or HCM3,18, suggesting that mutations affecting
different residues of these sarcomeric proteins can result in
different clinical outcomes. Similarly, mutations in the lamin A/C
gene (LMNA) can originate several different diseases including
dilated cardiomyopathy 1A, Emery-Dreyfuss muscular dystrophy,
lipodystrophy, mandibuloacral dysplasia, limb-girdle muscular
dystrophy and Hutchinson-Gilford progeria syndrome. With the
exception of Hutchinson-Gilford progeria, caused by de novo
mutations affecting the C-terminal end of the protein, or
lipodystrophy, caused by inherited mutations usually near the
C-terminal end of the protein, all other pathologies are caused by
LMNA mutations that are scattered along the length of the
protein, and no genotype–phenotype segregation has been
established19–21. Similarly, mutations in FHL1, which usually
cause skeletal muscle disease, have been shown to cause HCM
with left ventricular diastolic dysfunction without skeletal muscle
affection22,23. This situation is closely parallel to that of the FLNC
mutations described in the present work, which are mainly
clustered on the N- and C-terminal parts of the protein, but none
of them overlap with previously described mutations causing
myoﬁbrillar myopathy16. Nevertheless, and taking into account
that ﬁlamin C interacts with many proteins involved in muscle
function, we can speculate that some mutations may have more
impact in cardiac muscle or in skeletal muscle, depending on
whether they affect speciﬁc domains or binding surfaces of this
sarcomeric protein. In this regard, the ﬁnding that expression of
these mutants in cardiac myocytes resulted in the formation of
larger protein aggregates than when expressed in C2C12
myotubes supports a model in which interaction of these
mutants with tissue-speciﬁc proteins, contributes to the
predominant cardiac phenotype.
In this regard, it is also remarkable that about one-third of
myoﬁbrillar myopathy patients with the most frequent mutation
in FLNC (the German variant, p.W2710X) are reported to have
cardiac abnormalities, although only two out of 25 patients had
cardiomyopathy with left ventricular dysfunction13. These data
suggest that the clinical spectrum of the different ﬁlaminopathies
is highly dependent on the site of mutation within the ﬁlamin C
molecule. In fact, and despite the absence of histological
abnormalities or ﬁlamin C aggregates in skeletal muscle from
our HCM patients, analysis of heart samples from two of them
subjected to heart transplant due to their HCM revealed
myoﬁbrillar disarray and sarcomeric aggregates in cardiac
muscle similar to those described in skeletal muscle of patients
with myoﬁbrillar myopathy. Furthermore, we have demonstrated
that at least three of the mutations identiﬁed in HCM families
disrupt the functional structure of the protein and lead to the
formation of protein aggregates when expressed in cardiac
myoblasts, further supporting a functional role for these
mutations. In addition, expression of two of these mutants,
including p.A1539T for which FLNC protein aggregates were
not detected, resulted in the formation of actin aggregates.
This suggests that expression of this mutant is also able to
alter the cytoskeleton structure, raising the possibility that
actin aggregation might contribute to HCM in some of these
patients.
Although loss of function mutations might contribute to the
development of HCM in these patients, the fact that Flnc-
deﬁcient mice show a disruption of the skeletal muscle structure
without apparent cardiac involvement24 suggests that other
mechanisms might be implicated in this process. Thus, the
previous ﬁnding that Flnc-knockout mice are neonatally lethal,
whereas heterozygous mice show no obvious phenotype, supports
the hypothesis that the formation of protein aggregates, and not
the lack of function of FLNC mutants, is responsible for the
muscle alterations observed in these pathologies. In this regard,
the fact that three out of the four mutants analysed in this study
form protein aggregates when overexpressed in rat cardiac
myocytes supports this hypothesis. Nevertheless, we cannot rule
out that other molecular mechanisms might also contribute to the
aetiology of the disease and might explain the fact that one of the
four analyzed mutations (p.A1539T) did not form protein
aggregates in our in vitro experimental system. In addition, and
despite the apparent absence of a cardiac phenotype in mice
lacking the last eight exons of Flnc, the medaka mutant zacro,
which results from a homozygous nonsense mutation in the 15th
rod domain of ﬁlamin C25, shows an enlarged heart and
progressive skeletal muscle degeneration, thus reinforcing our
proposal that this protein is central for cardiac function.
Notably, we found a higher proportion of sudden cardiac
deaths among families with FLNC mutations when compared
with cases without FLNC mutations, thus providing an additional
clinical dimension to the identiﬁcation of high-risk patients
carrying these mutations. In this regard, we observed that among
the two families with the same FLNC mutation (p.A1539T), there
were three cases of sudden death and one patient was
transplanted, suggesting that this particular amino-acid change
might have a greater impact on the clinical evolution of the
disease. The presence of two asymptomatic carriers within these
families (ages 12 and 52) allows a closer monitoring of these
individuals to identify potential symptoms of HCM. Thus,
echocardiographic follow-up of individual CAR304_II-5 (age
52) revealed an incipient hypertrophic septum (11mm), compa-
tible with an initial phase of HCM development. These results
underscore the utility of these ﬁndings for the early detection of at
risk individuals who can also beneﬁt for speciﬁc treatment.
Finally, we realize that the relatively small size of some of the
families used in this study constitutes a limitation to achieve
statistical signiﬁcance by relaying only in sequencing data. In this
regard, and in agreement with the guidelines for investigating
causality of sequence variants in human disease26, we have
combined sequencing information with expression data in the
heart, statistical analysis of population-based variants in FLNC, as
well as performed extensive functional validation of the identiﬁed
mutations, which support the role of FLNC mutations in familial
HCM. Nevertheless, future studies aimed at expanding the
number of HCM families will be necessary to deﬁne the precise
role of FLNC in HCM. In conclusion, by using exome-capture
and next-generation sequencing we have identiﬁed FLNC as a
potential new gene implicated in HMC, thereby demonstrating
the utility of these approaches for the rapid and efﬁcient
identiﬁcation of the genetic causes of inherited diseases. This
work also underscores the relevance of ﬁlamins in cardiac
pathologies and provides new insights for the appropriate
molecular diagnosis and clinical management of carriers of
FLNC mutations in HCM families.
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Methods
Study subjects. All participants had provided written informed consent approved
by the Ethics Review Board of the Hospital Universitario Central de Asturias
(Oviedo, Spain). Peripheral blood leukocytes were collected and used for isolation
of genomic DNA. Study subjects included a proband with a family history of HCM,
as well as other members of her family (Supplementary Table 2, and Fig. 1). A
panel of 92 additional patients with the same clinical characteristics and lacking
mutations in known sarcomeric genes were also studied (Supplementary Table 3).
Exome sequencing. Genomic DNA was extracted from peripheral blood leuko-
cytes with a Qiagen kit according to the manufacturer’s instructions (Qiagen,
Germany). Exome capture from patient CAR_III-1 genomic DNA was performed
using a SureSelectXT Human All Exon 50Mb Kit (Agilent). In brief, 3 mg of
genomic DNA was sheared with a Covaris S2 instrument and used for the con-
struction of a paired-end sequencing library as described in the paired-end
sequencing sample preparation protocol provided by Illumina27. Enrichment of
exonic sequences was then performed using the Sure Select Human All Exon 50Mb
Kit (Agilent Technologies) following the manufacturer’s instructions. Exon-
enriched DNA was pulled down by magnetic beads coated with streptavidin
(Invitrogen), followed by washing, elution and 18 additional cycles of ampliﬁcation
of the captured library. The enriched library was sequenced (2 76 bp) using a
HiSeq 2000 instrument (Illumina).
Exome sequence data analysis. Sequence data were analysed using a custom
pipeline as previously described5. In brief, reads were mapped to the human
reference genome (GRCh37) using BWA28 with the sampe option, and a BAM ﬁle
was generated using SAMtools29. Optical or PCR duplicates were removed using
Picard (http://picard.sourceforge.net/index.shtml). Bases were initially called using
SAMtools and BCFtools. Variants present in dbSNP135 with a minor allele
frequency 40.01, or present in 42% of individuals of Spanish origin without
previous history of HCM for which exome data were available as part of the CLL-
ICGC project30, were discarded as common polymorphisms. Variants potentially
affecting protein function, including non-synonymous variants, frameshifts in the
coding sequence, or variants potentially affecting splicing, were analysed.
Clinical validation sequencing. For the validation studies, the exonic regions of
FLNC were ampliﬁed and sequenced in a validation series of 92 patients with HCM
using speciﬁc primers and SMIPS31, a pooled-sequencing approach combined with
next-generation sequencing (Supplementary Table 4). Data analysis was performed
using custom scripts to identify variants in the pooled sequence data, and
mutations were conﬁrmed in additional subjects from the same families using
Sanger sequencing. For the calculation of LOD scores, parametric linkage was
performed using the program LINKAGE32. Only family members for which
genotype was available were considered for the analysis, and other members were
scored as unknown, with the exception of individuals I-1, II-1 and I-6 from family
2, who were affected and obligate carriers but for whom no DNA was available, and
were considered affected carriers.
Skeletal muscle studies. To evaluate skeletal muscle affection, HCM patients
were studied by electromyography and/or magnetic resonance. In addition, tru-cut
muscular biopsies were performed to patients CAR2_III-1 and CAR125_II-1. Both
signed an informed consent for the use of samples in research, according to the
national regulations of LIB 14/2007. Samples were obtained from the right quad-
riceps through a small (2mm) skin incision and a tru-cut biopsy needle (Care
Fusion 14G 7.6 cm). The skin and subcutaneous tissue down to the muscle sheet
were previously inﬁltrated with 2% Mepivacaine (Braun). A small sample was
immediately ﬁxed in glutaraldehyde, at room temperature. In addition, a small
piece was ﬁxed in 5% formalin and parafﬁn embedded. The remaining of the
muscular sample was observed under the stereoscopic microscope. Using a thin
gauge, ﬁbres were oriented transversally and snap-frozen on liquid nitrogen-
freezing isopentane. Thin 3-mm sections were obtained with a cryostat and stored
at  80 C before use.
Histochemistry. Histochemical techniques were performed according to the lit-
erature33 for Engel-Gomori trichrome, succinate dehydrogenase (SDH), NADH
dehydrogenase (NADH), cytochrome C oxidase (COX), esterase and adenosine
triphosphatase (ATPase) pH 9.4.
Immunohistochemistry. Immunohistochemistry was performed on parafﬁn 3-mm
thick sections, previously heated at 60 C, then cleared and dehydrated in xylene
and graded alcohols. Antigen retrieval was performed by heating in with a Tris
Borate EDTA buffer (pH 8.4). Endogen peroxidase activity was quenched by
incubation in TBS-T containing 3% hydrogen peroxide. Each incubation step was
carried out at room temperature and followed by three sequential washes in TBS-T.
To block non-speciﬁc binding, tissues were incubated for 20min in TBS-T con-
taining 10% bovine serum albumin (BSA). Samples were incubated with a primary
rabbit polyclonal antibody against ﬁlamin C (Novus Biologicals, Littleton, CO) at
1:25 dilution, followed by incubations with a biotinylated OMNImap secondary
antibody for 15min, peroxidase-labelled streptavidin and diaminobenzidine sub-
strate. Control immunohistochemical staining was performed following the same
procedure but omitting the primary antibody. Procedures were performed in a
Discovery Ventana system (Roche). Slides were dehydrated and mounted with a
xylene-based medium.
Electron microscopy. Muscle samples were ﬁxed in glutaraldehyde for 3 h, and
post-ﬁxed in osmic tetroxide and embedded in Epon resin (Embed-812) using an
automated tissue processor (Reichert Lynx). Ultrathin sections were prepared with
a diamond knife using an ultramicrotome (Ultracut Reigert-Jung), and post stained
with uranyl acetate and lead citrate. The ultrastructural observations were per-
formed using a Jeol 1200 electron microscope equipped with a digital camera.
Heart samples. Heart samples from transplant receptors CAR242_I-1 and
CAR304_II-4 were studied in parallel with control hearts from a healthy donor and
three HCM patients without mutations in FLNC, one of them with a mutation in
the sarcomeric gene MYH7, and two others without mutations in known genes.
Coronary sections were performed following 5% formaldehyde ﬁxation. Repre-
sentative samples of right and left ventricles, septal area and coronaries were
parafﬁn embedded. Serial 3-mm sections were obtained for H&E staining. Addi-
tional sections were used for immunohistochemistry. The procedure was the same
as for the peripheral muscle with a control sample placed on the same slide for each
case. For ultrastructural studies, small (2mm) left ventricle samples were obtained
from parafﬁn blocks using a razor blade. Samples were deparafﬁnized and prepared
for ultrastructural studies following the same procedure as the peripheral muscle
biopsies.
Directed mutagenesis of full-length ﬁlamin C. A full-length cDNA clone for
ﬁlamin C (NM_001458) with an N-terminal Myc-DDK-Tag was obtained from
OriGene (Rockville, MD). Site-directed mutagenesis was performed to generate
four clones with the p.A1539T, p.V123A, p.R2133H and p.A2430V mutations,
respectively, using a QuikChange II XL Site-Directed Mutagenesis kit according to
the manufacturer’s recommendations (Stratagene) and speciﬁc oligonucleotides
(Supplementary Table 5). Introduction of the correct mutation and absence of
additional mutations was veriﬁed by Sanger sequencing.
Cell culture and immunoﬂuorescence. Rat cardiac myoblast cell line H9C2 was
kindly provided by Dr M. Mittelbrunn. Cells were grown in DMEM supplemented
with 10% new born calf serum and L-Glutamine. Cells were transfected using
Amaxa SF cell line 4D-Nucleofector X Kit by Lonza following the manufacturer’s
instructions. In brief, 3 106 cells were nucleofected with 2 mg of each plasmid and
48 h after transfection the presence of protein aggregates was analysed by
sequential detergent extraction of proteins. Neonatal Rat Cardiac Myocytes were
obtained by Lonza. Cells were grown in rCMC Medium, containing Basal Media
(RCBM Medium) supplemented with Horse serum, Fetal Bovine Serum, Genta-
micin/Amphotericin-B and Bromo-20-deoxyuridine (BrdU) according to the
manufacturer’s instructions. Cells were transfected using the Amaxa rat Cardio-
myocyte Neo Nucleofector Kit by Lonza. In brief, 1 106 cells were nucleofected
with 2 mg of each plasmid and 48 h after transfection cells were analysed by
immunoﬂuorescence. Basically, cells were washed with PBS, ﬁxed with 4% (v/v)
formaldehyde and permeabilized by incubation with 0.2% Triton X-100 in PBS.
Cells were washed, blocked with 10% normal goat serum in PBS, followed by
incubation using an anti-DYKDDDDK Tag Antibody (Cell Signaling) diluted in
1% FCS in PBS. Following multiple washes, cells were incubated with an Alexa
Fluor 488-conjugated goat anti-rabbit IgG antibody (1:500) and with Phalloidin-
Alexa 568 (Molecular Probes) for 1 h at room temperature. Nuclei were stained
with 40 ,6-diamidino-2-phenylindole (DAPI), coverslips were mounted on slides
and cells imaged with a Leica SP2 confocal microscope (Leica Microsystems).
C2C12 myoblasts were grown on Dulbecco’s modiﬁed Eagle’s medium (DMEM,
Gibco) containing 4mM L-glutamine (Gibco) and 10% fetal calf serum (Gibco),
and sodium pyruvate. To express wild-type and mutant ﬁlamin C, cells were
transiently transfected with 1 mg of the appropriate plasmid using Lipofectamine
(Invitrogen), grown for 24 h and then placed on glass coverslips. To induce
myotube formation, cells were switched to medium containing 5% horse serum,
cultured for 72 h and analysed by immunoﬂuorescence as above.
Sequential detergent extraction of proteins and western blot. For protein
extraction, cultured cells were washed twice with 1 PBS and resuspended in TEN
buffer (10mM TrisHCl pH 8.0, 1mM EDTA, 100mM NaCl, 50mM iodoaceta-
mide) supplemented with complete protease inhibitor cocktail without EDTA
(Roche) and 0.5% NP-40. Cell lysates were centrifuged at 13,000 g for 5min, and
supernatant was conserved as soluble fraction. The insoluble fraction was further
solubilized using TEN buffer containing 2% SDS, sonicated and centrifuged at
16,000 g for 10min. This latter supernatant was conserved as the insoluble fraction.
Protein concentration was evaluated with the bicinchoninic acid technique (Pierce
BCA protein assay kit). Proteins were run in SDS-PAGE gels, transferred to
nitrocellulose membranes, blocked with 5% non-fat dry milk in TBS-T buffer
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(20mM Tris pH 7.4, 150mM NaCl, 0.05% Tween 20) and incubated overnight at
4 C with the following primary antibodies: anti-DDK tag antibody (Cell Signaling)
and anti-actin (Sigma). Primary antibodies were detected with horseradish per-
oxidase-conjugated species-speciﬁc secondary antibodies (Jackson Immunor-
esearch or Thermo Scientiﬁc) with Luminata Forte Western HRP Substrate
(Millipore) using a LAS-300 FUJIFILM.
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